Cognito TherapeuticsCognito Therapeutics
CT

Cognito Therapeutics

Developing a novel therapeutic approach for Alzheimer's disease.

2011Active

About

Cognito Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic approach for Alzheimer's disease. Their lead product candidate, Spectris™, is a non-invasive, wearable neurostimulation device designed to treat cognitive decline associated with Alzheimer's. The company aims to address the underlying pathology of the disease by modulating brain activity.

Technology stack

detected 2026-06-14
Est. monthly stack spend~$160/mo
CDN
Cloudflare
EmailMicrosoft 365
Stack
Webflow
Analytics
Google Tag Manager
Video
Vimeo
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Cognito Therapeutics do?

Cognito Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic approach for Alzheimer's disease. Their lead product candidate, Spectris™, is a non-invasive, wearable neurostimulation device designed to treat cognitive decline associated with Alzheimer's. The company aims to address the underlying pathology of the disease by modulating brain activity.

How much funding has Cognito Therapeutics raised?

Cognito Therapeutics has raised a total of $213M in funding. The most recent round on record is Series C.

Where is Cognito Therapeutics headquartered?

Cognito Therapeutics is headquartered in Boston, Massachusetts, USA.

When was Cognito Therapeutics founded?

Cognito Therapeutics was founded in 2011.

What industry does Cognito Therapeutics operate in?

Cognito Therapeutics operates in Biotechnology, Medical Devices, Neuroscience, Healthcare.